Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 257-182-1 | CAS number: 51410-72-1
Neurotoxicity
Administrative data
Description of key information
Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test including neurotoxicity assessment; oral (gavage); rat (Sprague Dawley [Crl:CD(SD)BR]), m/f (OECD guideline 422, GLP): NOAEL(neurotoxicity) = 1000 mg/kg bw/d
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No indication of neurotoxicity was found in a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test according to OECD Guideline 422 (22 March 1996) MAPTAC was administered to 10 Sprague Dawley [Crl:CD(SD)BR] rats/sex/dose orally by gavage at dose levels of 0 (control), 100, 300 and 1000 mg/kg bw/d. Males were treated for a total of 38 days including 2 weeks prior to pairing and continuously thereafter, up to the day before necropsy.
Females were dosed throughout the study including 2 weeks before pairing, thereafter during pairing, gestation and lactation periods until Day 3 post partum.
Observation of animals at removal from the cage and in an open arena (neurotoxicity assessment) did not reveal changes attributable to the test item. Reduction in motor activity and reduced grip strength (first trial only) observed in males of the high dose group were noted at the end of treatment period when compared to controls. Considering that no differences were noted in other correlated neuromotory tests (second trial of grip strength, landing footsplay and rearing measurements in the open arena) this finding was considered incidental.
On the basis of the results obtained in the study, the NOAEL for neurotoxicity was 1000 mg/kg bw/d (males/females).
No human data are available for neurotoxicity. However, there is no reason to believe that these results from rat would not be applicable to humans.
Justification for selection of effect on neurotoxicity via oral route endpoint:
OECD guideline 422 study including neurotoxicity assessment, no deviations, GLP
Justification for classification or non-classification
Based on the available data MAPTAC does not need to be classified for neurotoxicity according to Directive 67/548/EEC as well as CLP, EU GHS (Regulation 1272/2008/EC) and therefore labelling is not necessary.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
